Phase II Study of S-877489 in Pediatric Patients with Attention-deficit/Hyperactivity Disorder
Latest Information Update: 14 Dec 2021
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Shionogi; Shire
- 14 Dec 2021 New trial record